Tubulointerstitial Disease

The answer first

Acute interstitial nephritis (AIN) is the great mimic of acute kidney injury — an immune-mediated inflammation of the renal interstitium that presents as a quiet, subacute creatinine drift with unimpressive urine, and that is caused by a drug until proven otherwise [1]. Three rules carry you through the DWE and the long case [1] [5]:

1. Suspect it in every unexplained AKI. The textbook allergic syndrome — fever, rash, eosinophilia — is the exception, not the rule. Modern drug-induced AIN is usually just a creatinine that will not stop rising, and the triad appears together in only a small minority of biopsy-proven cases [3] [4].
2. Stop the culprit drug immediately. Withdrawal of the offending agent is the one intervention with consistent outcome data, and delay in withdrawal is associated with worse renal recovery — the steroid question always comes second [2].
3. Steroids are a decision, not a default. The evidence is entirely retrospective; benefit concentrates in patients treated early after biopsy confirmation with no contraindication. In an elderly polypharmacy patient with modest AKI, watchful waiting after drug withdrawal is a defensible, examinable position [2] [13].

---

AIN — the great AKI mimic

The typical modern case is unimpressive to look at, which is exactly why it is missed. A patient started on a drug weeks ago — a proton pump inhibitor, an antibiotic, an NSAID — has a creatinine that has drifted upward over days to weeks. There is no oliguria drama, no nephritic sediment, no nephrotic picture. The urine shows modest abnormalities at most, the kidneys are normal-sized on ultrasound, and the only real clue is the timeline [3] [6]. In biopsy series performed for unexplained AKI, AIN accounts for roughly 15–20% of diagnoses — common enough that "we never biopsied, so we never saw it" is a real phenomenon on every renal unit [1] [3].

The classic teaching — fever, rash, eosinophilia — comes from the methicillin era. In contemporary series each individual feature appears in only a minority of patients, and the full triad is present in about 10% or fewer of biopsy-proven drug-induced cases [4] [3]. Peripheral eosinophilia is present in a minority. What remains as the consistent signal is the drug exposure and the tempo: a subacute, non-oliguric creatinine rise days to weeks after the culprit began [6].

---

Causes — the drug chart first

Drugs now cause the large majority of AIN in modern series, displacing the infections that dominated older textbooks [3]. The classes worth knowing individually, because examiners test their peculiarities:

Proton pump inhibitors deserve their own paragraph because they dominate the modern long case. A nationwide nested case-control study found current PPI use carried a severalfold increased risk of AIN, and a systematic review of reported cases describes the typical patient: older, months into treatment, with none of the allergic features, presenting as unexplained CKD drift [9] [10]. Because PPIs are started casually and almost never reviewed, the drug is still on the chart when the biopsy comes back — which is why deprescribing is the centrepiece of the DCE defence [9].

Infections are the second category: AIN accompanies leptospirosis, tuberculosis, EBV and a range of bacterial and viral illnesses, usually as part of the systemic infection rather than an isolated renal event [1]. Tuberculosis also appears on the granulomatous interstitial nephritis list, where it competes with drugs and sarcoidosis [20].

Autoimmune and systemic causes complete the map: TINU syndrome (tubulointerstitial nephritis with uveitis), Sjögren syndrome, sarcoidosis, IgG4-related disease, and lupus [22] [21]. These matter for two reasons: they change management (the underlying disease dictates treatment), and they are the reason "no culprit drug" does not end the workup [20].

---

Pathophysiology — why the tubules fail quietly

Drug-induced AIN is an idiosyncratic, delayed-type (type IV) T-cell hypersensitivity — not a dose-dependent toxicity and not IgE-mediated, which is why it can appear after months of uneventful use and why prior tolerance means nothing [1] [5]. The drug (or its metabolite) acts as a hapten, binding tubular basement membrane or interstitial components, and the resulting lymphocytic response does the damage [1].

The cascade explains the clinical signature. Inflammation sits in the interstitium, not the glomerulus, so there is no heavy proteinuria (NSAIDs excepted), no dysmorphic haematuria, and no nephritic sediment — just a GFR that slides as tubular function and peritubular blood flow deteriorate [1]. It also explains the two prognostic facts examiners care about: recovery tracks the amount of fibrosis already laid down at biopsy, and both delayed drug withdrawal and delayed treatment allow more of it to accumulate [2] [4].

---

Diagnosis — urine clues, then the biopsy question

The urine gives you probability, not proof. The findings to name aloud, in the order examiners want them [6] [7]:

The pivotal modern data on urinary eosinophils comes from a biopsy-proven case series: urinary eosinophils performed poorly as a discriminator between AIN and other causes of kidney disease, in line with the original description that defined eosinophiluria across a broad clinical spectrum beyond AIN [7] [8]. The exam translation is blunt: eosinophiluria neither rules AIN in nor rules it out, and a question that hinges on it is testing whether you know its limits [7].

---

Management — stop the drug, then the steroid conversation

Step one is not steroids — it is the drug chart. Withdrawal of the culprit agent is the one intervention every study and every reviewer agrees on, and the retrospective data tie delay in withdrawal to worse recovery [2]. In the González series of drug-induced AIN, both delayed withdrawal and delayed steroid initiation were associated with worse final renal function — the message that timing, not just treatment, is the lever [2].

The steroid evidence — know it by name

There has never been an adequate randomised trial of corticosteroids in AIN; the entire evidence base is retrospective and confounded by indication. The DWE expects you to hold that uncertainty honestly and still have a working position [13] [14].

The defensible synthesis: offer corticosteroids to the patient who is early (within days of withdrawal, before fibrosis accumulates), biopsy-proven, has significant AKI, and has no contraindication — and make it a shared decision, because the evidence is observational and the harms (hyperglycaemia, infection, delirium, myopathy) are real, especially in the elderly polypharmacy patient who typifies PPI-induced disease [2] [13]. There is no mandate to treat every AIN with steroids; a modest AKI already recovering after withdrawal is legitimately watched [14].

When steroids are given, the commonly used regimen is prednisone about 1 mg/kg daily (up to roughly 60–80 mg) with a taper over about 8–12 weeks — intravenous methylprednisolone first in severe cases — acknowledging that the duration data argue against dragging the taper out [1] [2] [14].

[2] [14]

---

Checkpoint-inhibitor AIN — the oncology handshake

Immune checkpoint inhibitors (anti-PD-1, anti-PD-L1, anti-CTLA-4) have added a new, examinable chapter. AIN is the dominant lesion on biopsy in ICI-associated AKI, typically appearing weeks to months into therapy, often alongside other immune-related adverse events [12]. The mechanism fits the drug class: releasing T-cell brakes loses peripheral tolerance, and the kidney is one of the organs that pays for it [11].

Management is a negotiation, not a solo renal decision: hold the checkpoint inhibitor, treat with corticosteroids (most patients recover at least partial renal function), and decide on rechallenge jointly with oncology once renal function has stabilised — multicentre data show recurrent AKI occurs in a minority of rechallenged patients, so rechallenge is a real option when the cancer indication is strong, with close creatinine surveillance [11]. The viva-ready nuance: this is the one AIN setting where "stop the culprit drug forever" is explicitly negotiable, because the culprit may be the patient's only effective cancer therapy [11] [12].

---

The named syndromes — TINU, granulomatous, IgG4

TINU syndrome — tubulointerstitial nephritis with uveitis — is the trap with a physical sign. A patient (classically an adolescent or young adult, though it occurs at any age) presents with AIN, and the uveitis may precede, accompany or follow the nephritis by months; it is frequently relapsing [22]. The practical rules: ask about eye symptoms in every AIN, examine the eyes, get ophthalmology to slit-lamp them, and warn the patient that the uveitis can return after the kidneys have recovered [22].

Granulomatous interstitial nephritis has its own short differential: drugs and sarcoidosis are the commonest causes, with tuberculosis and other infections behind them — so granulomas on biopsy redirect the workup toward chest imaging, calcium, ACE and a TB assessment rather than simply lengthening the drug-stop list [20].

IgG4-related tubulointerstitial nephritis typically affects older men, often with other organ involvement (pancreas, salivary glands, retroperitoneum), a high serum IgG4, characteristic imaging lesions, and a plasma-cell-rich infiltrate with IgG4 staining on biopsy; it is notably steroid-responsive, which makes it the AIN variant you least want to miss [21].

---

Chronic tubulointerstitial nephritis — the slow burns

Chronic TIN presents differently: years of slowly progressive CKD, tubular dysfunction out of proportion to GFR (concentrating defects, distal acidification problems), modest proteinuria, bland sediment, and kidneys that may be small or scarred on imaging. The causes are the exam's favourites because each carries a story [17] [18]:

---

Recovery and prognosis

Recovery from AIN is slow and often incomplete, and saying so early is part of good consulting. Creatinine typically begins improving within days to weeks of drug withdrawal (faster with early steroids in the responders), but the nadir-to-plateau journey runs over weeks, and a substantial fraction of biopsy-proven patients are left with CKD — the series that track long-term function after steroids make this plain [2] [13]. The predictors of incomplete recovery are the same in every series: delayed withdrawal, delayed treatment, and interstitial fibrosis already present on biopsy [2] [4].

The follow-up plan is therefore part of the management, not an afterthought: repeat creatinine through the recovery arc, review blood pressure and proteinuria, avoid re-exposure to the culprit class, document the adverse drug reaction, and refer back to nephrology if function plateaus at a reduced eGFR — because "recovered from AIN" and "back at baseline" are not synonyms [1] [13].

---

The exam angles — DCE long case and data station

The long case is the biopsy-proven PPI AIN in a polypharmacy patient: a 74-year-old whose creatinine drifted for six weeks on omeprazole, no rash, no fever, eosinophils normal, biopsied when function failed to recover. The examiner's interest is never the histology — it is your medication reasoning: how you reconciled the chart, what you deprescribed and why, how you defended (or declined) steroids with observational evidence, how you counselled about incomplete recovery, and how you stopped the next doctor restarting a PPI "for reflux" without a plan [9] [2]. Bring a deprescribing framework (indication, benefit, harm, burden, patient priorities) and the open-disclosure obligation that comes with an iatrogenic injury [5].

The short case is a data station, not a bedside: urine microscopy showing sterile pyuria with white-cell casts, a drug chart containing a recently started agent, and a creatinine trend. The task is to integrate them — name AIN as the unifying diagnosis, state what you would stop, state when you would biopsy, and resist every invitation to lean on eosinophiluria or the absent rash [7] [8].

---

Exam traps, collected

References

1. [1]Praga M, González E. Acute interstitial nephritis Kidney Int, 2010.PMID 20336051
2. [2]González E, Gutiérrez E, Galeano C, et al. Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis Kidney Int, 2008.PMID 18185501
3. [3]Baker RJ, Pusey CD. The changing profile of acute tubulointerstitial nephritis Nephrol Dial Transplant, 2004.PMID 14671029
4. [4]Clarkson MR, Giblin L, O'Connell FP, et al. Acute interstitial nephritis: clinical features and response to corticosteroid therapy Nephrol Dial Transplant, 2004.PMID 15340098
5. [5]Moledina DG, Perazella MA. Drug-Induced Acute Interstitial Nephritis Clin J Am Soc Nephrol, 2017.PMID 28893923
6. [6]Raghavan R, Eknoyan G. Acute interstitial nephritis - a reappraisal and update Clin Nephrol, 2014.PMID 25079860
7. [7]Muriithi AK, Leung N, Valeri AM, et al. Biopsy-proven acute interstitial nephritis, 1993-2011: a case series Am J Kidney Dis, 2014.PMID 24927897
8. [8]Nolan CR 3rd, Anger MS, Kelleher SP. Eosinophiluria--a new method of detection and definition of the clinical spectrum N Engl J Med, 1986.PMID 2431314
9. [9]Blank ML, Parkin L, Paul C, Herbison P. A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use Kidney Int, 2014.PMID 24646856
10. [10]Sierra F, Suarez M, Rey M, Vela MF. Systematic review: Proton pump inhibitor-associated acute interstitial nephritis Aliment Pharmacol Ther, 2007.PMID 17661758
11. [11]Cortazar FB, Kibbelaar ZA, Glezerman IG, et al. Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study J Am Soc Nephrol, 2020.PMID 31896554
12. [12]Cortazar FB, Marrone KA, Troxell ML, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors Kidney Int, 2016.PMID 27282937
13. [13]Prendecki M, Tanna A, Salama AD, et al. Long-term outcome in biopsy-proven acute interstitial nephritis treated with steroids Clin Kidney J, 2017.PMID 28396740
14. [14]Fernandez-Juarez G, Perez JV, Caravaca-Fontán F, et al. Duration of Treatment with Corticosteroids and Recovery of Kidney Function in Acute Interstitial Nephritis Clin J Am Soc Nephrol, 2018.PMID 30397027
15. [15]Vanherweghem JL, Depierreux M, Tielemans C, et al. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs Lancet, 1993.PMID 8094166
16. [16]Grollman AP, Shibutani S, Moriya M, et al. Aristolochic acid and the etiology of endemic (Balkan) nephropathy Proc Natl Acad Sci U S A, 2007.PMID 17620607
17. [17]De Broe ME, Elseviers MM. Analgesic nephropathy N Engl J Med, 1998.PMID 9459649
18. [18]Markowitz GS, Radhakrishnan J, Kambham N, et al. Lithium nephrotoxicity: a progressive combined glomerular and tubulointerstitial nephropathy J Am Soc Nephrol, 2000.PMID 10906157
19. [19]Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal antiinflammatory drugs N Engl J Med, 1984.PMID 6363936
20. [20]Joss N, Morris S, Young B, Geddes C. Granulomatous interstitial nephritis Clin J Am Soc Nephrol, 2007.PMID 17699417
21. [21]Raissian Y, Nasr SH, Larsen CP, et al. Diagnosis of IgG4-related tubulointerstitial nephritis J Am Soc Nephrol, 2011.PMID 21719792
22. [22]Mackensen F, Billing H. Tubulointerstitial nephritis and uveitis syndrome Curr Opin Ophthalmol, 2009.PMID 19752730